Business Description

Description
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. The firm generates revenue from collaborative research, license, development and commercialization agreements.
Name Current Vs Industry Vs History
Cash-To-Debt 0.41
Equity-to-Asset -1.51
Debt-to-Equity -0.08
Debt-to-EBITDA -0.01
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -213.42
Distress
Grey
Safe
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 43.44
9-Day RSI 44.3
14-Day RSI 45.8
6-1 Month Momentum % -80.06
12-1 Month Momentum % -90.67

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.35
Quick Ratio 0.35
Cash Ratio 0.02
Days Sales Outstanding 172.05

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -49.6
Shareholder Yield % -76.69
Name Current Vs Industry Vs History
Operating Margin % -3712.26
Net Margin % -3550.32
FCF Margin % -2952.9
ROE % -1144.19
ROA % -405.72
ROIC % -3267.46
ROC (Joel Greenblatt) % -4741.92
ROCE % -1043.42

Financials (Next Earnings Date:2024-03-31 Est.)

VCNX's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:VCNX

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Vaccinex Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0.62
EPS (TTM) ($) -85.4
Beta 0.16
Volatility % 61.35
14-Day RSI 45.8
14-Day ATR ($) 1.210297
20-Day SMA ($) 9.27345
12-1 Month Momentum % -90.67
52-Week Range ($) 7.161 - 107.099999
Shares Outstanding (Mil) 1.17

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Vaccinex Inc Filings

Filing Date Document Date Form
No Filing Data

Vaccinex Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Vaccinex Inc Frequently Asked Questions

What is Vaccinex Inc(VCNX)'s stock price today?
The current price of VCNX is $8.76. The 52 week high of VCNX is $107.10 and 52 week low is $7.16.
When is next earnings date of Vaccinex Inc(VCNX)?
The next earnings date of Vaccinex Inc(VCNX) is 2024-03-31 Est..
Does Vaccinex Inc(VCNX) pay dividends? If so, how much?
Vaccinex Inc(VCNX) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1